ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications
See the rest here:
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of updated Phase 3 PFS and OS data demonstrating clinical benefits in efficacy and tolerability of oral paclitaxel versus IVP in patients with metastatic breast cancer (MBC). The findings further support the superiority of increased ORR observed with oral paclitaxel. These data were presented today during a spotlight poster presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS).
SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). The trials will evaluate the safety, pharmacokinetics and efficacy of a single injection of STI-2020 in healthy volunteers and outpatient COVID-19 patients with mild symptoms.
– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –
Go here to read the rest:
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
The digital press release with multimedia content can be accessed here:
Visit link:
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on DANYELZA® (naxitamab-gqgk) for the treatment of Refractory/Relapsed High-Risk Neuroblastoma was given at the ESMO Immuno-Oncology Virtual Congress 2020, which is being held December 9 through December 12, 2020. The DANYELZA data was presented by Dr. Jaume Mora from SJD Barcelona Children's Hospital, Spain and Dr. Daniel A. Morgenstern from The Hospital for Sick Children, Toronto, Canada.
More here:
Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.
Read the rest here:
SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer...
–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503––Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity–
TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has presented the results of its Hodgkin’s lymphoma (HL) clinical study at ASH 2020.
Go here to read the rest:
Telo Genomics Presents at ASH 2020 The Results of Hodgkin’s Lymphoma Clinical Study
WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced continued progress and future growth drivers related to its immuno-dermatology platform and pipeline, which will be highlighted during today’s Virtual Investor Day at 11:00 am ET.